| Dr Eric Lerche, DO | |
|
5246 N Royal Dr, Traverse City, MI 49684-6984 | |
| (231) 935-0957 | |
| Not Available |
| Full Name | Dr Eric Lerche |
|---|---|
| Gender | Male |
| Speciality | Orthopedic Surgery |
| Experience | 15 Years |
| Location | 5246 N Royal Dr, Traverse City, Michigan |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1225264005 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207X00000X | Orthopaedic Surgery | 5101018200 (Michigan) | Primary |
| 207XX0801X | Orthopaedic Surgery - Orthopaedic Trauma | 2014-00880 (North Carolina) | Secondary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Great Lakes Home Healthcare Specialists | Traverse city, MI | Home health agency |
| Munson Home Care | Traverse city, MI | Home health agency |
| Residential Home Health And Hospice | Lapeer, MI | Home health agency |
| Munson Medical Center | Traverse city, MI | Hospital |
| Munson Healthcare Otsego Memorial Hospital | Gaylord, MI | Hospital |
| Paul Oliver Memorial Hospital | Frankfort, MI | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Munson Medical Center | 3072426287 | 257 |
| Eric B Lerche Do Pc | 4284948274 | 2 |
| Munson Healthcare Otsego Memorial Hospital | 8325942535 | 72 |
News Archive
Looking at the retina in the eyes of patients with cerebral malaria has provided scientists with a vital insight into why malaria infection in the brain is so deadly.
In an original article coauthored by John M. Boyce, MD; Nancy L. Havill, MT; and Brent A. Moore, PhD, "Terminal Decontamination of Patient Rooms Using an Automated Mobile UV Light Unit", the research team from the Hospital of Saint Raphael and the Yale University School of Medicine ". . . demonstrated that an automated, portable UV light device significantly reduced aerobic colony counts on high-touch surfaces in patient rooms.
ViroPharma Incorporated, an international biopharmaceutical company committed to developing and commercializing innovative products that address unmet medical needs and rare diseases, today announced the results of a Phase 2 study of VP20621 (non-toxigenic Clostridium difficile; NTCD) a novel treatment approach for preventing recurrent C. difficile infections.
In-home test kits, coupled with patient education, help parents reduce allergen levels in their homes, according to scientists from the National Institutes of Health. The researchers found that parents may become more motivated to participate in allergen reduction interventions, when they can actually see results for themselves.
Researchers at LSTM are looking at new ways to create and deliver medications for a wide range of immune-medicated neuropathies, by developing new synthetic versions of the treatment currently seen as the last resort option by doctors; intravenous immunoglobulin (IVIg) therapy.
› Verified 8 days ago
| Entity Name | Munson Medical Center |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1083761860 PECOS PAC ID: 3072426287 Enrollment ID: O20040108000904 |
News Archive
Looking at the retina in the eyes of patients with cerebral malaria has provided scientists with a vital insight into why malaria infection in the brain is so deadly.
In an original article coauthored by John M. Boyce, MD; Nancy L. Havill, MT; and Brent A. Moore, PhD, "Terminal Decontamination of Patient Rooms Using an Automated Mobile UV Light Unit", the research team from the Hospital of Saint Raphael and the Yale University School of Medicine ". . . demonstrated that an automated, portable UV light device significantly reduced aerobic colony counts on high-touch surfaces in patient rooms.
ViroPharma Incorporated, an international biopharmaceutical company committed to developing and commercializing innovative products that address unmet medical needs and rare diseases, today announced the results of a Phase 2 study of VP20621 (non-toxigenic Clostridium difficile; NTCD) a novel treatment approach for preventing recurrent C. difficile infections.
In-home test kits, coupled with patient education, help parents reduce allergen levels in their homes, according to scientists from the National Institutes of Health. The researchers found that parents may become more motivated to participate in allergen reduction interventions, when they can actually see results for themselves.
Researchers at LSTM are looking at new ways to create and deliver medications for a wide range of immune-medicated neuropathies, by developing new synthetic versions of the treatment currently seen as the last resort option by doctors; intravenous immunoglobulin (IVIg) therapy.
› Verified 8 days ago
| Entity Name | Munson Healthcare Otsego Memorial Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1164628426 PECOS PAC ID: 8325942535 Enrollment ID: O20040305000525 |
News Archive
Looking at the retina in the eyes of patients with cerebral malaria has provided scientists with a vital insight into why malaria infection in the brain is so deadly.
In an original article coauthored by John M. Boyce, MD; Nancy L. Havill, MT; and Brent A. Moore, PhD, "Terminal Decontamination of Patient Rooms Using an Automated Mobile UV Light Unit", the research team from the Hospital of Saint Raphael and the Yale University School of Medicine ". . . demonstrated that an automated, portable UV light device significantly reduced aerobic colony counts on high-touch surfaces in patient rooms.
ViroPharma Incorporated, an international biopharmaceutical company committed to developing and commercializing innovative products that address unmet medical needs and rare diseases, today announced the results of a Phase 2 study of VP20621 (non-toxigenic Clostridium difficile; NTCD) a novel treatment approach for preventing recurrent C. difficile infections.
In-home test kits, coupled with patient education, help parents reduce allergen levels in their homes, according to scientists from the National Institutes of Health. The researchers found that parents may become more motivated to participate in allergen reduction interventions, when they can actually see results for themselves.
Researchers at LSTM are looking at new ways to create and deliver medications for a wide range of immune-medicated neuropathies, by developing new synthetic versions of the treatment currently seen as the last resort option by doctors; intravenous immunoglobulin (IVIg) therapy.
› Verified 8 days ago
| Entity Name | Eric B Lerche Do Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1790176972 PECOS PAC ID: 4284948274 Enrollment ID: O20150804006004 |
News Archive
Looking at the retina in the eyes of patients with cerebral malaria has provided scientists with a vital insight into why malaria infection in the brain is so deadly.
In an original article coauthored by John M. Boyce, MD; Nancy L. Havill, MT; and Brent A. Moore, PhD, "Terminal Decontamination of Patient Rooms Using an Automated Mobile UV Light Unit", the research team from the Hospital of Saint Raphael and the Yale University School of Medicine ". . . demonstrated that an automated, portable UV light device significantly reduced aerobic colony counts on high-touch surfaces in patient rooms.
ViroPharma Incorporated, an international biopharmaceutical company committed to developing and commercializing innovative products that address unmet medical needs and rare diseases, today announced the results of a Phase 2 study of VP20621 (non-toxigenic Clostridium difficile; NTCD) a novel treatment approach for preventing recurrent C. difficile infections.
In-home test kits, coupled with patient education, help parents reduce allergen levels in their homes, according to scientists from the National Institutes of Health. The researchers found that parents may become more motivated to participate in allergen reduction interventions, when they can actually see results for themselves.
Researchers at LSTM are looking at new ways to create and deliver medications for a wide range of immune-medicated neuropathies, by developing new synthetic versions of the treatment currently seen as the last resort option by doctors; intravenous immunoglobulin (IVIg) therapy.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Eric Lerche, DO 5246 N Royal Dr, Traverse City, MI 49684-6984 Ph: (231) 935-0957 | Dr Eric Lerche, DO 5246 N Royal Dr, Traverse City, MI 49684-6984 Ph: (231) 935-0957 |
News Archive
Looking at the retina in the eyes of patients with cerebral malaria has provided scientists with a vital insight into why malaria infection in the brain is so deadly.
In an original article coauthored by John M. Boyce, MD; Nancy L. Havill, MT; and Brent A. Moore, PhD, "Terminal Decontamination of Patient Rooms Using an Automated Mobile UV Light Unit", the research team from the Hospital of Saint Raphael and the Yale University School of Medicine ". . . demonstrated that an automated, portable UV light device significantly reduced aerobic colony counts on high-touch surfaces in patient rooms.
ViroPharma Incorporated, an international biopharmaceutical company committed to developing and commercializing innovative products that address unmet medical needs and rare diseases, today announced the results of a Phase 2 study of VP20621 (non-toxigenic Clostridium difficile; NTCD) a novel treatment approach for preventing recurrent C. difficile infections.
In-home test kits, coupled with patient education, help parents reduce allergen levels in their homes, according to scientists from the National Institutes of Health. The researchers found that parents may become more motivated to participate in allergen reduction interventions, when they can actually see results for themselves.
Researchers at LSTM are looking at new ways to create and deliver medications for a wide range of immune-medicated neuropathies, by developing new synthetic versions of the treatment currently seen as the last resort option by doctors; intravenous immunoglobulin (IVIg) therapy.
› Verified 8 days ago
Dr. Justin Joseph Hollander, D.O. Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 5246 N Royal Dr, Traverse City, MI 49684 Phone: 231-935-0957 Fax: 231-935-0960 | |
Thomas Freeman Jr., MD Orthopedic Surgery Medicare: Medicare Enrolled Practice Location: 4045 W Royal Dr, Traverse City, MI 49684 Phone: 231-935-0900 Fax: 833-471-4024 | |
Dr. Thomas V O'hagan, M.D. Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 4045 W Royal Dr, Traverse City, MI 49684 Phone: 231-935-0900 | |
Christopher Robert Chuinard, M.D. Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 4045 W Royal Dr, Traverse City, MI 49684 Phone: 231-935-0900 Fax: 231-935-0308 | |
Dr. John Robert Reineck, M.D. Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 4045 W Royal Dr, Traverse City, MI 49684 Phone: 231-935-0900 Fax: 231-935-0308 | |
Dr. Joseph M Mcgraw, M.D. Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 4045 W Royal Dr, Traverse City, MI 49684 Phone: 231-935-0900 Fax: 231-935-0308 |